Kurt J. Edinger

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

37

H-Index

1

About

Kurt J. Edinger is a pharmaceutical scientist whose work centers on drug metabolism and pharmacokinetics, with a particular focus on developing high-throughput methodologies to accelerate drug discovery. His most cited contribution, "An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates" (2007, 37 citations), introduced the MetFast assay—an automated platform that rapidly evaluates the in vitro metabolic stability of potential drug candidates using microsomal cytochrome P450 enzymes. This innovation streamlined early-stage pharmaceutical profiling, enabling researchers to identify compounds with favorable first-pass metabolism more efficiently. By integrating liquid chromatography-mass spectrometry with automation, Edinger’s work addressed a critical bottleneck in drug development, reducing the time and resources needed to assess drug candidates. His contributions have been instrumental in advancing preclinical screening protocols, making him a key figure in the optimization of drug discovery pipelines.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates
37 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago